NCT00658463View on ClinicalTrials.gov

Effects of Rosuvastatin on the, in Vivo, Kinetic of apoB and apoA1, Using Stable Isotopes, in Type 2 Diabetic Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

January 31, 2006

Primary Completion Date

June 30, 2007

Study Completion Date

September 30, 2007

Conditions
Diabetes
Interventions
DRUG

Rosuvastatin

rosuvastatin 20 mg/day during 6 weeks versus placebo during 6 weeks in a cross-over design

DRUG

Placebo

Placebo

Trial Locations (1)

21000

Centre Hospitalier Universitaire de Dijon, Dijon

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

Centre Hospitalier Universitaire Dijon

OTHER

NCT00658463 - Effects of Rosuvastatin on the, in Vivo, Kinetic of apoB and apoA1, Using Stable Isotopes, in Type 2 Diabetic Patients | Biotech Hunter | Biotech Hunter